Prodrugs of ALOX-15 inhibitors and methods of using the same
Described herein are compounds and pharmaceutical compositions containing such compounds which are prodrugs of ALOX-15 inhibitors. Also described herein are methods for using such compounds in the treatment of disease.
1. A compound having the structure of Formula (I):
wherein:
R 1 is —P(O)(OH)
R 2 is halogen;
R 3 , R 4 , and R 5 are each independently selected from H, halogen, and C 1-6 alkyl optionally substituted with one, two, or three R 13 ;
R 6 is selected from H and C 1-6 alkyl; and
each R 13 is independently selected from halogen;
or a pharmaceutically acceptable salt or solvate thereof.
2. The compound of claim 1 , or a pharmaceutically acceptable salt or solvate thereof, having the structure of Formula (Ia):
3. The compound of claim 2 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 , R 4 , and R 5 are each independently selected from H, halogen, and unsubstituted C 1-6 alkyl.
4. The compound claim 3 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 , R 4 , and R 5 are each independently selected from H and halogen.
5. The compound of claim 3 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 , R 4 , and R 5 are each independently halogen.
6. The compound of claim 5 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 6 is H.
7. The compound of claim 5 , or a pharmaceutically acceptable salt or solvate thereof, wherein R 6 is C 1-6 alkyl.
8. The compound of claim 1 having the structure:
or a pharmaceutically acceptable salt or solvate thereof.
9. The compound of claim 1 selected from:
or a pharmaceutically acceptable salt or solvate thereof.